Avidity Partners Management LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
Avidity Partners Management LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$41,729,299
+56.5%
801,100
+58.9%
1.68%
+190.7%
Q4 2022$26,671,680
-59.1%
504,000
-64.1%
0.58%
-56.4%
Q3 2022$65,258,000
+47.4%
1,402,500
+80.9%
1.33%
+30.6%
Q2 2022$44,266,000775,5041.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders